EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG

View source ↗

Summary

EMA authorised Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, expanding treatment options in rheumatoid arthritis, juvenile …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Hidradenitis Suppurativa
• Juvenile Idiopathic Arthritis
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• Libmyris (adalimumab)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;Arthritis, Juvenile Rheumatoid;Spondylitis, Ankylosing;Arthritis, Psoriatic;Psoriasis;Hidradenitis Suppurativa;Crohn Disease;Colitis, Ulcerative;Uveitis. MAH: Stada Arzneimittel AG. Decision date: 19/03/2026